Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study of GC022F CAR-T Cell Immunotherapy for Relapsed or Refractory B- ALL

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04129099
Recruitment Status : Recruiting
First Posted : October 16, 2019
Last Update Posted : May 28, 2020
Sponsor:
Collaborators:
Gracell Biotechnology Ltd.
Beijing Lu Daopei Hospital
Information provided by (Responsible Party):
Hebei Yanda Ludaopei Hospital

Brief Summary:
The study is an early, open, single-centered trial. The aim of this study is to evaluate the safety and tolerance of GC022F CAR-T cell immunotherapy in relapsed or refractory B-ALL. The study will include 18 subjects to receive GC022F therapy.

Condition or disease Intervention/treatment Phase
B-cell Acute Lymphoblastic Leukemia Biological: GC022F Early Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 18 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Study of GC022F CAR-T Cell Immunotherapy for Relapsed or Refractory B- ALL
Actual Study Start Date : October 22, 2019
Estimated Primary Completion Date : September 2020
Estimated Study Completion Date : June 2022


Arm Intervention/treatment
Experimental: CAR-T treatment group
The patients will receive one dose of GC022F. GC022F dosage ranges from 6×10^4 to 1.5×10^5 CAR+T/Kg.
Biological: GC022F
GC022F is the CAR-T cell immunotherapy targeted CD19 and CD22. The subjects will receive GC022F as one dose. The dosage ranges from 6×10^4 to 1.5×10^5 CAR+T/Kg.




Primary Outcome Measures :
  1. Incidence and severity of treatment related Adverse Events, CRS and Neurotoxicity (Safety and tolerability) [ Time Frame: 2 years ]
    Adverse events(AEs) will be collected and graded according to ASTCT consensus(for Cytokine Release Syndrome, CRS and Immune Effector Cell-Associated Neurotoxicity Syndrome, ICANS) and CTCAE v5.0(for AE except CRS/ICANS )


Secondary Outcome Measures :
  1. CAR copies and concentration of GC022F in peripheral blood, bone marrow and CSF (amplification and persistence) [ Time Frame: 2 years ]
    GC022F CAR copies and cells in peripheral blood, bone marrow and CSF will be measured by qPCR and FCM in 2 years

  2. Overall response rate of patients who received GC022F infusion (efficacy) [ Time Frame: 2 years ]
    Overall response rate will be estimated as the percents of patients who achieved CR or CRi.

  3. Concentraiton of anti-GC022F antibody after infusion (humoral immune response) [ Time Frame: 2 years ]
    After GC022F infusion, GC022F antibody in peripheral blood will be measured in 2 years



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   2 Years to 70 Years   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Aged 2-70 years;
  2. Eastern cooperative oncology group (ECOG) performance status of 0 to 2;
  3. Life expectancy≥12 weeks;
  4. CD19 and/or CD22 tumor expression demonstrated in bone marrow or peripheral blood by flow cytometry;
  5. Relapsed or refractory B- ALL: a) Refractory B- ALL: MRD≥0.1% or fail to achieve a CR after 2 cycles of a standard induction chemotherapy regimen or one-line/multi-line salvage chemotherapy; b) Relapsed B- ALL: Relapse after remission for the first time in 12 months or relapse after one-line/multi-line salvage chemotherapy; Relapse is defined as MRD≥0.1% or recurrence of primitive cell in peripheral blood or bone marrow(>5%) after remission; c)Relapse after autologous stem cell transplantation or allogeneic hematopoietic stem cell transplantation; Relapse is defined as above; d)Patients with Philadelphia chromosome positive(Ph+) ALL were eligible if they were intolerant to or had failed two lines of tyrosine kinase inhibitor (TKI) therapy, or had t315i mutation.
  6. Did not receive hematopoietic stem cell transplantation≤6 months prior to enrollment;
  7. Adequate organ function defined as: a) Creatinine clearance (as estimated by Cockcroft Gault) >60 mL/min; b) Serum ALT/AST <2.5 ULN; c) Total bilirubin <1.5 ULN (subjects with Gilbert's syndrome≤3 ULN); d) Cardiac ejection fraction≥50%, no evidence of clinically significant pericardial effusion as determined by an ECHO; e) No clinically significant pleural effusion; f) Baseline oxygen saturation >92% on room air;
  8. Females of reproductive age must be in non-lactation period. Females of childbearing potential must have a negative serum or urine pregnancy test. All subjects must use medical-approved-contraception (such as intrauterine device and contraceptive drugs) during the period of trial and in 2 years after cell transfusion therapy; Males should avoid sperm donation;
  9. Venous access can be established, peripheral blood mononuclear cells (PBMC) can be collected in researcher's judgement;
  10. The subject agrees to and sign informed consent form, willing and able to comply with the planned visit, research, treatment planning, laboratory and other test procedures.

Exclusion Criteria:

  1. Isolated extra-medullary disease relapse;
  2. Central nervous system leukemia involved CNS-3;
  3. Concomitant malignancy other than cured non-melanoma skin cancer or cervical carcinoma in situ or localized prostate cancer or superficial bladder cancer or ductal carcinoma in situ or diagnosis of other malignancy exceeds 5 years without relapse or treatment during the 5 years;
  4. Any result of the following virology tests is positive: HIV; HCV; HBsAg; or HBCAb positive with HBV DNA copies positive; TPPA;
  5. Live vaccine ≤4 weeks prior to enrollment;
  6. For Ph+ ALL, TKI therapy ≤1 weeks prior to enrollment;
  7. Presence of ≥ grade 2 acute graft-versus-host disease (GVHD, Glucksberg criteria) or extensive chronic GVHD (Seattle criteria) that require treatment ≤4 weeks prior to enrollment, or during the study period the subject is required to receive anti- GCHD therapy in researcher's judgement;
  8. Presence of concomitant disease that require systemic steroids or other immune suppressive therapy during the study period in researcher's judgement;
  9. Allogeneic cell therapy (such as donor lymphocyte infusion, DLI) ≤4 weeks prior to enrollment;
  10. CNS stereotactic radiotherapy ≤4 weeks prior to enrollment;
  11. Toxicities related to previous therapy did not relieved to ≤1 grade, except hematological toxicity and alopecia;
  12. Known life-threatening hypersensitivity to cyclophosphamide or fludarabine, or presence of other intolerant conditions, or severe allergic constitution;
  13. Patients with active autoimmune disease (e.g., systemic lupus erythematosus, sjogren syndrome, rheumatoid arthritis, psoriasis, multiple sclerosis, inflammatory bowel disease, Hashimoto's thyroiditis, hypothyroidism which can be controlled by thyroid hormone replacement therapy is an exception);
  14. For patients that underwent or plan to undergo major surgical operation before CAR-T treatment, surgical operation happened ≤4 weeks prior to enrollment, or did not be fully recovered and clinically stable prior to enrollment, or be anticipated to undergo major surgical operation during the study;
  15. Any unstable cardiovascular diseases happened ≤6 months prior to enrollment, including but not limited to, unstable angina, myocardial infarction, heart failure (NYHA grade≥ III grade), severe arrhythmia that require drug interference, cardiac angioplasty/coronary stent implantation/ cardiac bypass surgery ≤6 months prior to enrollment;
  16. Presence of central nervous system(CNS) disease or disease history, including epilepsy, cerebral Ischemia/bleeding, dementia, cerebellar disease, any autoimmune diseases that involve CNS;
  17. Presence of active infection that require therapy ≤2 weeks prior to apheresis;
  18. Any other conditions that researcher think it is inappropriate for the subject to anticipate the trial.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04129099


Contacts
Layout table for location contacts
Contact: Junfang Yang, Bachelor 13522084342 Yangjunfang77@163.com

Locations
Layout table for location information
China, Hebei
Hebei Yanda Ludaopei Hospital Recruiting
Sanhe, Hebei, China, 065200
Contact: Peihua Lu, PhD&MD    +86-0316-3306393      
Sponsors and Collaborators
Hebei Yanda Ludaopei Hospital
Gracell Biotechnology Ltd.
Beijing Lu Daopei Hospital
Investigators
Layout table for investigator information
Principal Investigator: Junfang Yang, Bachelor Hebei Yanda Ludaopei Hospital
Layout table for additonal information
Responsible Party: Hebei Yanda Ludaopei Hospital
ClinicalTrials.gov Identifier: NCT04129099    
Other Study ID Numbers: PGC0006
First Posted: October 16, 2019    Key Record Dates
Last Update Posted: May 28, 2020
Last Verified: May 2020

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Leukemia, Lymphoid
Leukemia
Neoplasms by Histologic Type
Neoplasms
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases